Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Authors:
- Srivandana AkshintalaSASrivandana Akshintala
- R. Taylor. SundbyRSR. Taylor. Sundby
- Donna BernsteinDBDonna Bernstein
- John W. GlodJGJohn W. Glod
- Rosandra N. KaplanRKRosandra N. Kaplan
- Marielle E. YoheMYMarielle E. Yohe
- Andrea M. GrossAGAndrea M. Gross
- Joanne DerdakJDJoanne Derdak
- Haiyan LeiHLHaiyan Lei
- Alexander PanAPAlexander Pan
- Eva DombiEDEva Dombi
- Isabel Palacio-YanceIPIsabel Palacio-Yance
- 3 July 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (17) , 3329-3339
Abstract
Purpose: Antibodies against insulin-like growth factor (IGF) type 1 receptor have shown meaningful but transient tumor responses in patients with rhabdomyosarcoma (RMS). The SRC family member YES has been shown to mediate IGF type 1 receptor (IGF-1R) antibody acquired resistance, and cotargeting IGF-1R and YES resulted in sustained responses in murine RMS models. We conducted a phase I trial of the anti–IGF-1R antibody ganitumab combined with dasatinib, a multi-kinase inhibitor targeting YES, in patients with RMS (NCT03041701). Patients and Methods: Patients with relapsed/refractory alveolar or embryonal RMS and measurable disease were eligible. All patients received ganitumab 18 mg/kg intravenously every 2 weeks. Dasatinib dose was 60 mg/m2/dose (max 100 mg) oral once daily [dose level (DL)1] or 60 mg/m2/dose (max 70 mg) twice daily (DL2). A 3+3 dose escalation design was used, and maximum tolerated dose (MTD) was determined on the basis of cycle 1 dose-limiting toxicities (DLT). Results: Thirteen eligible patients, median age 18 years (range 8–29) enrolled. Median number of prior systemic therapies was 3; all had received prior radiation. Of 11 toxicity-evaluable patients, 1/6 had a DLT at DL1 (diarrhea) and 2/5 had a DLT at DL2 (pneumonitis, hematuria) confirming DL1 as MTD. Of nine response-evaluable patients, one had a confirmed partial response for four cycles, and one had stable disease for six cycles. Genomic studies from cell-free DNA correlated with disease response. Conclusions: The combination of dasatinib 60 mg/m2/dose daily and ganitumab 18 mg/kg every 2 weeks was safe and tolerable. This combination had a disease control rate of 22% at 5 months.Keywords
All Related Versions
Funding Information
- National Cancer Institute
- USC Norris Comprehensive Cancer Center (5P30CA014089-45)
This publication has 82 references indexed in Scilit:
- Epitope-Specific Mechanisms of IGF1R Inhibition by GanitumabPLOS ONE, 2013
- Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2012
- PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk StratificationJournal of Clinical Oncology, 2012
- Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2012
- MotifMap: integrative genome-wide maps of regulatory motif sites for model speciesBMC Bioinformatics, 2011
- Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I ConsortiumJournal of Clinical Oncology, 2011
- Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyThe Lancet Oncology, 2010
- Molecular Classification of Rhabdomyosarcoma—Genotypic and Phenotypic Determinants of DiagnosisThe American Journal of Pathology, 2009
- MotifMap: a human genome-wide map of candidate regulatory motif sitesBioinformatics, 2008
- Addiction to Elevated Insulin-like Growth Factor I Receptor and Initial Modulation of the AKT Pathway Define the Responsiveness of Rhabdomyosarcoma to the Targeting AntibodyCancer Research, 2008